Potential combination of ibrutinib with gamma delta T-cell therapy in CLL

Iris de Weerdt

Iris de Weerdt, MD from the Academic Medical Center University of Amsterdam, Amsterdam, Netherlands, talks to us about the potential of combining gamma delta T-cell therapy with ibrutinib due to the drug’s off-target effect on ITK inhibition and improving T-cell function. She notes that there are possibilities of increased toxicity with this combination but states that this is not a major concern as clinical trial data have not presented such observations so far. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video